Literature DB >> 16985915

The evolving definition of advanced prostate cancer.

Judd W Moul.   

Abstract

Each year more patients present with prostate cancer at increasingly younger ages and with earlier stage disease, resulting in the potential for longer survival time, longer-term hormonal therapy, and a heightened risk of developing biochemical recurrence after treatment. It seems clear that clinicians need to broaden the definition of "advanced" prostate cancer to include recent knowledge that will influence the form and timing of treatment as well as the monitoring of disease progression. A more contemporary definition should include patients with lower-grade disease and with an increased risk of progression and/or death from prostate cancer along with those with widely disseminated metastatic disease. Treatment alternatives for these patients should be evaluated based on a risk stratification equation toward a goal of the greatest efficacy and the least patient harm over time given that increasing numbers of these patients are entering treatment long before they develop widespread osteoblastic metastases.

Entities:  

Year:  2004        PMID: 16985915      PMCID: PMC1472896     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  24 in total

1.  A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.

Authors:  M W Kattan; J A Eastham; A M Stapleton; T M Wheeler; P T Scardino
Journal:  J Natl Cancer Inst       Date:  1998-05-20       Impact factor: 13.506

2.  Natural history of progression after PSA elevation following radical prostatectomy.

Authors:  C R Pound; A W Partin; M A Eisenberger; D W Chan; J D Pearson; P C Walsh
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

3.  Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases.

Authors:  J W Moul; R R Connelly; D P Lubeck; J J Bauer; L Sun; S C Flanders; G D Grossfeld; P R Carroll
Journal:  J Urol       Date:  2001-10       Impact factor: 7.450

4.  Osteoporosis after orchiectomy for prostate cancer.

Authors:  H W Daniell
Journal:  J Urol       Date:  1997-02       Impact factor: 7.450

5.  Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.

Authors:  Anthony V D'Amico; Ming-Hui Chen; Kimberly A Roehl; William J Catalona
Journal:  N Engl J Med       Date:  2004-07-08       Impact factor: 91.245

Review 6.  Cancer statistics, 2004.

Authors:  Ahmedin Jemal; Ram C Tiwari; Taylor Murray; Asma Ghafoor; Alicia Samuels; Elizabeth Ward; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2004 Jan-Feb       Impact factor: 508.702

7.  Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era.

Authors:  Anthony V D'Amico; Judd Moul; Peter R Carroll; Leon Sun; Deborah Lubeck; Ming-Hui Chen
Journal:  J Clin Oncol       Date:  2003-06-01       Impact factor: 44.544

8.  Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.

Authors:  Judd W Moul; Hongyu Wu; Leon Sun; David G McLeod; Christopher Amling; Timothy Donahue; Leo Kusuda; Wade Sexton; Keith O'Reilly; Javier Hernandez; Andrew Chung; Douglas Soderdahl
Journal:  J Urol       Date:  2004-03       Impact factor: 7.450

9.  Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy.

Authors:  A W Partin; S Piantadosi; M G Sanda; J I Epstein; F F Marshall; J L Mohler; C B Brendler; P C Walsh; J W Simons
Journal:  Urology       Date:  1995-05       Impact factor: 2.649

10.  Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database.

Authors:  Judd W Moul; Hongyu Wu; Leon Sun; David G McLeod; Christopher Amling; Raymond Lance; Leo Kusuda; Timothy Donahue; John Foley; Andrew Chung; Wade Sexton; Douglas Soderdahl; Norman M Rich
Journal:  Surgery       Date:  2002-08       Impact factor: 3.982

View more
  12 in total

Review 1.  Interventional therapy in malignant conditions of the prostate.

Authors:  Attila Kovács; Michael Pinkawa
Journal:  Radiologe       Date:  2019-12       Impact factor: 0.635

Review 2.  Long non-coding RNAs and their potential impact on diagnosis, prognosis, and therapy in prostate cancer: racial, ethnic, and geographical considerations.

Authors:  Rebecca Morgan; Willian Abraham da Silveira; Ryan Christopher Kelly; Ian Overton; Emma H Allott; Gary Hardiman
Journal:  Expert Rev Mol Diagn       Date:  2021-11-25       Impact factor: 5.225

Review 3.  Prostate cancer relevant antigens and enzymes for targeted drug delivery.

Authors:  Ashutosh Barve; Wei Jin; Kun Cheng
Journal:  J Control Release       Date:  2014-05-27       Impact factor: 9.776

4.  NADiA ProsVue prostate-specific antigen slope is an independent prognostic marker for identifying men at reduced risk of clinical recurrence of prostate cancer after radical prostatectomy.

Authors:  Judd W Moul; Hans Lilja; O John Semmes; Raymond S Lance; Robert L Vessella; Martin Fleisher; Clarisse Mazzola; Mark J Sarno; Barbara Stevens; Robert E Klem; Jonathan E McDermed; Melissa T Triebell; Thomas H Adams
Journal:  Urology       Date:  2012-10-26       Impact factor: 2.649

5.  Analysis of Clinical Trials on Therapies for Prostate Cancer in Mainland China and Globally from 2010 to 2020.

Authors:  Kun Chen; Kehua Jiang; Lannan Tang; Xiaolong Chen; Jianxin Hu; Fa Sun
Journal:  Front Oncol       Date:  2021-05-12       Impact factor: 6.244

6.  Preparation of 68Ga-PSMA-11 with a Synthesis Module for Micro PET-CT Imaging of PSMA Expression during Prostate Cancer Progression.

Authors:  Yuebing Wang; Guoqiang Shao; Jianping Wu; Can Cui; Shimin Zang; Fan Qiu; Ruipeng Jia; Zizheng Wang; Feng Wang
Journal:  Contrast Media Mol Imaging       Date:  2018-04-26       Impact factor: 3.161

7.  Leuprorelin depot injection: patient considerations in the management of prostatic cancer.

Authors:  Zinelabidine Abouelfadel; E David Crawford
Journal:  Ther Clin Risk Manag       Date:  2008-04       Impact factor: 2.423

8.  Survival outcomes of younger men (< 55 years) undergoing radical prostatectomy.

Authors:  Lynn Tan; Luke L Wang; Weranja Ranasinghe; Raj Persad; Damien Bolton; Nathan Lawrentschuk; Shomik Sengupta
Journal:  Prostate Int       Date:  2017-08-09

Review 9.  Proton therapy- the modality of choice for future radiation therapy management of Prostate Cancer?

Authors:  Sophie Mangan; Michelle Leech
Journal:  Tech Innov Patient Support Radiat Oncol       Date:  2019-10-11

10.  Current Mental Distress Among Men With a History of Radical Prostatectomy and Related Adverse Correlates.

Authors:  Gabriela Ilie; Joshua White; Ross Mason; Ricardo Rendon; Greg Bailly; Joseph Lawen; David Bowes; Nikhilesh Patil; Derek Wilke; Cody MacDonald; Robert Rutledge; David Bell
Journal:  Am J Mens Health       Date:  2020 Sep-Oct
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.